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Ischemia-reperfusion (I-R) injury after liver transplantation (LT) induces intra- and/or extrahepatic nonanastomotic ischemic-
type biliary lesions (ITBLs). Subsequent bile duct stricture is a signiﬁcant cause of morbidity and even mortality in patients who
underwent LT. Although the pathogenesis of ITBLs is multifactorial, there are three main interconnected mechanisms responsible
for their formation: cold and warm I-R injury, injury induced by cytotoxic bile salts, and immunological-mediated injury. Cold
and warm ischemic insult can induce direct injury to the cholangiocytes and/or damage to the arterioles of the peribiliary vascular
plexus, which in turn leads to apoptosis and necrosis of the cholangiocytes. Liver grafts from suboptimal or extended-criteria
donors are more susceptible to cold and warm I-R injury and develop more easily ITBLs than normal livers. This paper, focusing
on liver I-R injury, reviews the risk factors and mechanisms leading to ITBLs following LT.
1.Introduction
After liver transplantation (LT), the incidence of biliary com-
plications, which include a wide spectrum of functional and
anatomicalabnormalitiesvariesfrom10to30%[1–3].These
biliary complications lead to an increase of graft dysfunction
and patient morbidity and in some cases even to graft loss
[4] and retransplantation [5]. They are associated with an
increased mortality rate (8 to 15%) [6].
Liver ischemia-reperfusion (I-R) injury during trans-
plantation occurs at diﬀerent periodes [7]. The ﬁrst, after
liver explantation from the donor and storage on ice at 0◦ to
4◦C, is a variable but generally long period of cold ischemia.
The time of vascular anastomosis, when the liver is removed
from ice until its implantation in the recipient, represents
the second, relatively shorter period of warm I-R injury. In
this period of ischemia, the liver warms slowly up to a tem-
perature of 12.5◦C during the realization of suprahepatic
cava and portal vein anastomoses, and to a temperature of
34◦C,oncehepaticarteryanastomosisisperformed[8].Now
the liver is fully revascularized and graft temperature stabi-
lizes. Normothermic reperfusion of the implanted liver with
the recipient’s blood at 37◦C delineates the third period.
Liver ischemia-reperfusion injury following LT causes up
to 10% of early transplant failures and can lead to acute
and chronic rejection [9]. Moreover, liver I-R injury is as-
sociated with intra- and/or extrahepatic nonanastomotic
biliary strictures following liver transplantation [4, 10–13].
The ischemic injury itself, a localized process of cellular
metabolic disturbances, results from glycogen consumption,
lack of oxygen supply and adenosine triphosphate (ATP)
depletion [14]. Reperfusion, which consists of initial phase
injury(within2hafterreperfusion)andlatephaseinjury(6–
48 hours after reperfusion), aggravates the cellular injuries
caused by the ischemic period [9, 15–17].
Although all types of ischemia share common mecha-
nisms cold ischemia of the liver is characterized mainly by
injury to sinusoidal lining cells and disruption of the micro-
circulation, whereas warm ischemia results primarily in2 Journal of Transplantation
Kupﬀer cell (KC)-derived cytotoxic molecule-mediated hep-
atocellular injury [17–19].
LiverI-Rinjuryduringtransplantationinvolvesnecessar-
ily the peribiliary plexus resulting in endothelial cell activa-
tion, which triggers a cascade of events leading to microvas-
cular thrombosis, microcirculatory disturbances and again
ischemia [10, 20]. Stricture formation, biliary apoptosis,
necrosis, and cholangitis are the results and may even lead to
progressive graft failure. Indeed, it seems that cholangiocytes
are more sensible to the ischemic insult than the liver paren-
chyma [10].
2. Anatomy and Blood Supply of
the Biliary System
The human biliary system is divided into extrahepatic and
intrahepatic bile ducts and is lined by biliary epithelial
cells (or cholangiocytes). The classical extrahepatic biliary
anatomy consists of a right and left hepatic duct draining
the right and left liver lobes, respectively [21–23]. The fusion
of the right and left hepatic ducts gives rise to the common
hepatic duct (choledochus) [21–23]. The intrahepatic bile
ducts are further sub-divided into large and small bile ducts
[24–26]. They represent that part of the biliary tree proximal
to the conﬂuence of the hepatic ducts [27] extending from
the canals of Hering to the large extrahepatic ducts [24–26].
Small ductules that are lined by 4-5 cholangiocytes have
a basement membrane, tight junctions between cells, and
microvilli projecting into the bile duct lumen [25]. In larger
bile ducts cholangiocytes too are progressively larger and
more columnar in shape. Ten to twelve cholangiocytes line
al a r g e rb i l ed u c t[ 28, 29]. The vascular plexus of the biliary
system is composed of branches arising directly from the
right and left hepatic arteries (and accessory hepatic arteries
when present) and their segmental branches and indirectly
from the gastroduodenal artery via the arteries supplying the
common bile duct [21–23]. This peribiliary vascular plexus
is arranged around the extra- and intrahepatic biliary tree
in normal liver [25]. The peribiliary vascular plexus delivers
blood to the sinusoids both through lobular branches and
through peribiliary branches into the portal vein [25]. In
very small portal spaces a small capillary, representing the
terminal branches of the hepatic artery, can continue the
course of the arteriole and eventually run into the sinusoids
[25]. In large portal spaces, the peribiliary vascular plexus is
an anastomotic network between short collateral arterioles
arising from the same arterial branches. Since the blood
ﬂows in the opposite direction to the bile (from the large
towards the small vessels), the peribiliary vascular plexus
presentsacountercurrentstream[25,30].Theveinsdraining
the surface of the bile ducts follow closely the arterial plexus
and drain into the marginal veins. The marginal veins end in
subcapsular capillaries related to the hilum of the liver [31].
3. Classiﬁcationof BiliaryComplications
Following LT
Bile duct strictures following LT have been classiﬁed as
anastomotic strictures (ASs) and nonanastomotic biliary
strictures (NAS) [32]. ASs are isolated strictures at the site
of the bile duct anastomosis (choledochocholedochostomy
orcholedochojejunostomyreconstruction),whileNASscon-
cern strictures located in both, the extrahepatic and intra-
hepatic biliary system of the liver graft [32]. NASs occur
after hepatic artery thrombosis (HAT), but also with an
open hepatic artery [32]. NASs with an open hepatic artery
represent a separate entity and are generally referred to
as ischemic-type biliary lesions (ITBLs) [32, 33]. ITBLs
were also termed as “ischemic-type biliary complications
or ITBC” [3], “ischemic cholangitis” [34] and “ischemic
cholangiopathy” [35]. NAS were subclassiﬁed according to
theiretiology:(a)NASsecondarytomiaroangiopathicinjury
(hepatic arterial thrombosis or stenosis), (b) ITBLs sec-
ondarytomicroangiopathicinjury(preservationinjury,pro-
longed cold and warm ischemia times, donation after cardiac
death, and prolonged use of dopamine in the donor), and
(c) ITBLs secondary to immunogenetic injury (ABO incom-
patibility, rejection, autoimmune hepatic disease, CMV
infection, and chemokines polymorphisms) [36].
4. Incidence andRisk Factorsof
ITBLs Following LT
The incidence of ITBLs following LT is 5–15% [33]. This
great variability may be partially due to the diﬀerent deﬁ-
nitions used for ITBLs. Although most ITBLs secondary to
ischemiclesionsoccurwithin1yearafterthetransplantation,
their prevalence continues to increase with time after liver
transplantation [5]. ITBLs appearing more than 1 year after
transplantation are mainly related to immunological causes
[5].
Risk factors involved in the development of ITBLs are old
donor age [36, 37], prolonged cold and warm ischemia times
[4, 10–12], non-heart-beating donors (NHBD) [38, 39],
graft steatosis [40, 41], some graft perfusion methods [42],
high viscosity of cold storage solutions [43, 44], prolonged
use of dopamine in the donor [45], and posttransplant liver
cytolysis and cholestasis due to I-R injury [46, 47]. In liver
transplantation, the increasing gap between the number of
patients awaiting an organ and the number of available
organs has led to the use of extended-criteria donor (ECD)
organs, including organs, which present risk factors men-
tioned above [48]. As livers from suboptimal donors or ECD
are more susceptible to I-R and preservation injury, pri-
mary nonfunction (PNF), initial poor graft function (IPGF),
delayed graft function (DFG), and also ITBLs are more
frequent in these organs [4, 12, 37, 38, 49, 50].
5.Pathomechanisms of ITBLs Following LT
ITBLs following liver transplantation result in bile duct
destruction and subsequent stricture formation; even a case
of sequestration of the bile duct has been described [51]. As
shown in Table 1, there are three main interconnected mech-
anisms causing ITBLs after LT: cold and warm I-R injury
[4, 13, 39, 44, 46, 52], injury induced by cytotoxic bile salts
[53–57], and immunological-mediated injury [4, 58–76].Journal of Transplantation 3
Table 1: Pathomechanisms leading to ITBLs after liver transplanta-
tion.
Type of injury
Ischemia reperfusion related
(i) Warm ischemia in the donor
(ii) Prolonged cold ischemia time
(iii) Reperfusion injury
(iv) High viscosity of cold preservation solutions
(v) Warm ischemia during graft implantation
(vi) Microcirculatory disturbances in the peribiliary capillary
plexus
Bile salts related
(i) Cytoprotective hydrophilic bile salts (decreased after liver
transplantation)
(ii) Cytotoxic hydrophobic bile salts (accumulated after liver
transplantation)
Insuﬃcient ﬂush out of bile from the bile ducts during liver
transplantation
High biliary bile salt/phospholipid ratio after liver
transplantation
Impaired vectorial bile duct secretion with intracellular
accumulation of bile salts in cholangiocytes
Impaired biliary secretion of the protecting cholangiocyte factor
HCO3(−)
Immune mediated
(i) ABO-incompatible liver transplantation
(ii) Acute rejection
(iii) Chronic rejection
(iv) Gender (female liver transplanted in male recipient)
(v) Cytomegalovirus (CMV) infection in the graft
(vi) Chemokine polymorphism in graft recipients (CC receptor 5
delta 32)
(vii) Preexisting autoimmune disease of the graft
Primary sclerosing cholangitis
Autoimmune hepatitis
(viii) Metalloproteinase (MMP) polymorphism in donor and
recipient graft
MM P-2 genotype polymorphism
6. Cold andWarm I-RInjuryand ITBLs
FollowingLT(Figures1 and2)
Cold ischemic storage of the liver graft and its reperfusion
produces injury to the biliary epithelium [2, 13] and is
strongly associated with the development of biliary strictures
including ITBLs [77].
As Kupﬀercellsaresituatedwithinthelumenofthesinu-
soid, they are in direct contact with the endothelial surface.
From this position when activated by I-R, they release ROS,
proinﬂammatory cytokines, such as tumor necrosis factor
alpha (TNFα) and oxidants into the circulation as well as
directing them to the endothelial layer and the underlying
hepatocytes [78]. Although ROSs are essential to cell life
at physiological levels, when overproduced they may be
responsible of IPGF after LT [79]. Increased production of
ROS is associated to reduced basal levels of intracellular
glutathione, a principal nonprotein thiol responsible for
maintaining intracellular redox status and protecting cells
against oxidative injury [80]. Glutathione has an important
role in the prevention of cellular ischemia-related oxidative
injury during liver preservation by reducing biliary tract
cell ROS production [10]. Glutathione present in bile may
prevent cholangiocyte injury by counteracting the cytotoxic
eﬀects of ROS within the biliary tract [2, 10]. Glutathione is
also one of the major determinants of bile acid-independent
bile ﬂow [81]. In animals, impaired biliary excretion of glu-
tathione may contribute to the decreased bile ﬂow after cold
ischemia [82]. Decreased biliary glutathione excretion is due
to impaired transport across the canalicular membrane [82],
but also to increased intrabiliary degradation by solubilized
γ-glutamyltranspeptidase (GGT) [83]. The resulting lower
biliary glutathione concentrations diminish the resistence of
the cholangiocytes to oxidative stress provoked by I-R [83,
84]andinducecholangiocyteapoptosis[84]throughtheloss
of the antiapoptotic protein B-cell CLL/lymphoma 2 protein
(Bcl-2) [85]. Thus, glutathione depletion might explain the
intense injury of bile ducts seen in LT [10, 11, 84, 86].
T h el a t eo rs u b a c u t ep h a s eo fI - Ri n j u r yi sap o l y m o r -
phonuclear (PMN) leukocyte-dependent process in which
the above described ROS generation is associated to cytokine
and chemokine expression [78, 87, 88].
The epithelial-lining cells of the biliary system are not
only exposed to proinﬂammatory mediators deriving from
intrahepatic sources, but also to those deriving from extra-
hepatic sources via arterial circulation [89]. These inﬂam-
matory mediators promote the invasion of PMNs into the
interstitium via the upregulation of adhesion molecules and
formation of chemotactic agents [87, 90]. PMNs can pene-
trate the ductal basal membrane and thus contribute to bile
duct injury [91]. Ductal cells are desquamated to the lumen
of the bile duct and, together with PMNs, they appear in bile
during the ﬁrst few days after LT [92–94]. There is a clear
relationship between postreperfusion hepatic biopsy ﬁnd-
ings (the degree of PMN inﬁltration and hepatocellular
necrosis of the graft) and biliary complications after liver
transplantation, including ITBLs [77].
PMNs and platelets synergistically exacerbate sinusoidal
endothelial cell injury by induction of apoptosis during
reperfusion. During cell anoxia, cholangiocytes are signif-
icantly more resistant to cell death than hepatocytes [10].
This is inverted after reoxygenation of the anoxic cells
(which mimics tissue reperfusion), when hepatocytes are
more resistant to cell death than cholangiocytes. The rate
of ROS formation by cholangiocytes during reoxygenation
is greater than in hepatocytes at this moment with concomi-
tant low basal levels of the antioxidant glutathione in cho-
langiocytes [10]. These ﬁndings suggest that bile duct injury
after LT is mainly caused during the reperfusion period [10].
Liver reoxygenation upregulates other apoptotic receptor ex-
pression than Fas and enhances apoptosis in human biliary
epithelial cells [20]. Tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) which binds TRAIL recep-
tor1/death receptor 4 (DR4) and TRAIL receptor2/death4 Journal of Transplantation
ITBLs
Apoptosis/necrosis of epithelial biliary cells
- ROS generation
- MPT induction mitochondrial alteration
- Oxydative changes of the bile canaliculi cytoskeleton
- ATP depletion
- Bile salt toxicity (biliary stasis during cold ischemia
time and after liver transplantation)
- Alteration of bile composition
- Microcirculatory disturbances
Cold/warm liver ischemia reperfusion
Liver transplantation
Figure 1:ColdandwarmliverI-RleadingtoITBLsfollowingLT.ROS:reactiveoxygen species;MPT:mitochondrialpermeabilitytransition;
ATP: adenosine triphosphate.
receptor 5 (DR5) membrane death receptors can activate
apoptosis [95]. Reoxygenation up-regulates DR4 and DR5
expression and enhances TRAIL-mediated apoptosis in hu-
man intrahepatic biliary epithelial cells [20].
Human bile epithelial cells [20]d on o tn o r m a l l ye x p r e s s
DR5 [96], but during reoxygenation an even increased DR5
expression of cholangiocytes can be observed [20]. Re-
oxygenation increases also the activity of caspase-8 and
caspase-3 in a TRAIL-dependent manner [20]. Some studies
demonstrated an association of a longer warm ischemia time
and a marked cholangiocyte apoptosis [20, 97]. Cholangio-
cyte apoptosis after cold and warm liver I-R is at least partly
involved in the pathogenesis of ITBLs after LT [86].
7.IntrahepaticCholestasis andPathological
EffectsofBileSaltsFollowingLT
7.1. Intrahepatic Cholestasis. Bile formation requires the
coordinated function of hepatocytes and intrahepatic cho-
langiocytes, which represent 2 to 5% of liver cells [98, 99].
Hepatocytes produce primary or hepatic bile, which per-
colates through the intrahepatic bile ducts. During this
journey, cholangiocytes modify the bile via secretory and
absorptive processes that provide additional bile water and
alkalinity [100–102]. Cholestasis is an impairment of bile
secretion, which results either from a functional defect at
the level of hepatocytes (hepatocellular cholestasis) or from
an impairment in bile secretion and ﬂow at the level of bile
ductules or ducts (ductular/ductal cholestasis) [103]. Intra-
hepaticcholestasisfollowinglivertransplantationiscommon
and generally subclinical [104–107]. However, when severe,
cholestasis may be associated with irreversible liver damage,
requiring retransplantation [104, 108]. One of the main
causes of intrahepatic cholestasis after LT is cold and warm
I-Rinjury[104,109].Undernormalconditions,bileproduc-
tion requires an active vectorial secretion of biliary con-
stituents from portal blood plasma into bile canaliculi [110].
An intact cytoskeleton is required for bile canalicular con-
traction, which is based on a pericanalicular web of contrac-
tile proteins, actin microﬁlaments, and cytokeratin interme-
diate ﬁlaments [111] acting as a pump to facilitate bile ﬂow
into the intrahepatic canalicular system [112, 113]. The bile
canaliculus is one of the liver structuresthat is early damaged
by I-R [105]. This oxidative stress-dependent structural
damage contributes to perturbate the bile acid transport
during ischemia. The resulting loss of microvilli and the
canalicular atony, decrease the bile ﬂow and lead to cholesta-
sis [105–107]. The impairment of bile canaliculi structure
following I-R, and postreperfusion biliary complications
observed in patients undergoing LT, may be due to an altered
reassociationofRasGTPase-activating-likeproteinIQGAP1,
a regulator molecule of bile canaliculi structure, with the
endocytic machinery, particularly with the endocytic multi-
meric (AP-2) and monomeric (clathrin) adaptors (proteins
that mediate the interactions between “address tickets” on
cargo proteins and clathrin, as clathrin cannot bind directly
to cargo or membranes) [114]. The maintenance of the hep-
atocyte bile secretion properties would then depend on their
ability to rapidly rereform integral adherent junctions and
maintain bile canaliculi structure upon reperfusion [114].
Although during 120min of ischemia or ATP depletion,
cell viability and integrity of tight junctions supported
by adherent junctions in cholangiocytes were maintained,
strikingalterationsinthesecondarystructureoftheirplasmaJournal of Transplantation 5
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Figure 2: Role of Kupﬀer cells and PMNs in cold and warm ischemia leading to the development of ITBLs following LT. The epithelial
lining of the biliary tree is exposed not only to proinﬂammatory mediators derived from extrahepatic sources, via arterial circulation, but
also to proinﬂammatory mediators derived from intrahepatic sources, such as inﬂammatory cells or Kupﬀer cells. These inﬂammatory
mediators promote the invasion of PMNs into the interstitium. PMNs then penetrate the ductal basal membrane and contribute to bile
duct injury. Thus the main event injury seems to be activation of Kupﬀer cells and recruitment and activation of PMNs leading to apoptosis
of epithelial biliary cells. PMN: polymorphonuclear neutrophils; ROS: reactive oxygen species; ATP: adenosine triphosphate; Na(+), K(+)-
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ligand (TRAIL) which binds TRAIL-receptor2/death receptor 5 (DR5); Muc1: mucine 1; Muc3A: mucine 3A; MMP-2: metalloproteinase-2.
membrane, with decrease of the basolateral interdigitations
and apical microvilli have been observed [115]. This reorga-
nization of cholangiocyte membrane domains represents an
early event in rat liver ischemia and contributes to impaired
vectorial bile duct secretion and postischemic cholestasis
[115].
During the ischemic phase failure of the sodium pump
or Na(+), K(+)-ATPase [116] leads to intracellular accu-
mulation of Na(+), edema, and swelling of Kupﬀer cells,
sinusoidal endothelial cells, and hepatocytes [117]. Hepato-
cellular Na(+), K(+)-ATPase is an important driving force
for bile secretion and has been localized in the basolateral
plasmamembranedomain[118,119].Bileaciduptakebythe
hepatocyte is a secondary active transport that is energized
by the Na(+) gradient maintained by the Na(+), K(+)-
ATPase. Thus, Na(+), K(+)-ATPase appears important in
coupling the energy from ATP to transport activity, resulting
in so-called bile acid-dependent bile ﬂow [120]. Decreased
Na(+), K(+)-ATPase activity following cold and warm I-R
results in apoptosis, necrosis, and shedding of biliary tract
epithelial cells [121]. Reasons for alterations of Na(+), K(+)-
ATPase activity after hypoxia and reoxygenation in the
perfused rat liver [122] and after cold and warm I-R in
human LT [123], may be direct alteration of the enzyme
catalytic subunit and modiﬁcation of its environment; ROS
released from activated Kupﬀer cells, changes in ATP levels
and in membrane lipid ﬂuidity and ionic distribution may
also contribute to Na(+), K(+)-ATPase activity disturbances
[122]. Moreover, a marked delay of functional recovery in
cultured biliary epithelial cells, which was provoked by ATP
depletion, induced intrahepatic bile duct injury following I-
R[ 124].6 Journal of Transplantation
7.2. Pathological Eﬀects of Bile Salts. Cholestasis induced by
I-R injury is characterized by dilatation of bile canaliculi
a n dl o s so fm i c r o v i l l i[ 105] and exposes hepatocytes and ch-
olangiocytes to an elevated concentration of toxic bile acids
[125].
Bile formation is an energy consuming process, which is
regulated by speciﬁc transport proteins situated in the mem-
brane of hepatocytes and cholangiocytes [126]. I-R can
induce selective and/or temporary modiﬁcation of the ex-
pression and function of some biliary transporters, leading
to abnormal bile composition and to toxic injury to the cho-
langiocytes [110, 127], as well as to the hepatocytes [98].
The toxic bile composition early after LT, characterized
by a low biliary phospholipid/bile salt ratio, is associated
with histological signs of injury of the small bile ducts in the
liver [51, 54, 56]. The most important apoptotic initiator in
cholangiocytes is the Fas receptor/Fas ligand pathway [128].
Human cholangiocytes express Fas receptor [129]. Activated
Fas receptor complexes on the plasma membrane cause
caspase-8 activation and trigger apoptosis [128]. By liver I-
Ra c t i v a t e dK u p ﬀer cells can potentiate cholestatic injury
through the synthesis of the proapoptotic Fas-independent
receptor TRAIL [130]. Then, as in a vicious circle, during
cholestasis bile acids themselves may initiate or aggravate
hepatocellular damage [131]. Toxic hydrophobic bile acids
retained in the hepatocytes during cholestasis initiate the
generation of ROS metabolites from mitochondria, leading
to lipid peroxidation and loss of cell viability [132–134]. The
mitochondrial oxidative stress triggers the mitochondrial
permeability transition (MPT), resulting in exaggerated
mitochondrial cytochrome c release and apoptosis [135].
Biliary secretion of HCO3(−) prevents the uncontrolled
membrane permeation of cytotoxic hydrophobic bile salts
by maintaining an alkaline pH near the apical surface of
hepatocytes and cholangiocytes [13, 136].
The cholangiocyte “protector” HCO3(−)s e c r e t i o nm a y
be disturbed after LT, as I-R results in altered expression
of the anion exchanger 2 (AE2) and of the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) proteins,
which regulate the biliary secretion [137].
Prolonged cold ischemia time during LT is associated
to a downregulation of membrane-associated Mucine 1
(Muc1), 3A (Muc3A), and 5B (Muc5B) expression [138,
139]. Mucines are expressed on the apical membrane of the
biliary epithelial cells and lubricate and protect these cells
from diverse injuries, including injury by cytotoxic bile salts
[140]. Decreased expression of Muc1 and Muc3A after LT
may favour the development of ITBLs [138].
8.ImmunologicallyMediatedITBLs
Following LT
8.1. ABO Incompatibility. In the past, liver transplantation
across ABO blood group barriers has been discouraged
because of multiple complications, particularly acute rejec-
tionandbiliarycomplications[58].However,organshortage
and new developed immunosuppressive agents decreasing
humoral rejection have led to an increased use of ABO-
incompatible liver for transplantation with acceptable results
concerning patient and graft survival rate [65, 141, 142].
Although in children, there is no obvious diﬀerence in the
outcome of ABO-compatible LT and ABO-incompatible LT,
in adults graft survival rate after ABO-incompatible LT is not
so satisfactory [65]. Moreover, the incidence of ITBLs after
ABO-incompatibleLTinadultsismuchhigherthaninABO-
compatible LT [60, 65, 67].
ABO blood group antigens are expressed on both, bile
duct epithelium and vascular endothelial cells [143, 144].
Donor ABH antigen expression up to 150 days after LT is
associated with a high incidence of late, severe biliary stric-
tures (82%), hepatic artery complications (24%), decreased
graft survival (44%), and acute cellular rejection [60].
Persisting ABH antigen expression after ABO-incompatible
LT is often the consequence of the vascular occlusion. Sub-
sequent ischemic injuries caused by endothelial lesions in-
creasethesusceptibilitytoimmunologicinjuryofbiliarycells
leadingtoITBLs[62,67,145].Preexistingprimarysclerosing
cholangitis and autoimmune hepatitis are also associated
with a higher incidence of ITBLs [75, 76, 146].
8.2. Acute and Chronic Rejection. In liver allograft rejection,
most tissue damage occurs as a consequenceof direct cellular
immunologic injury to the bile duct epithelium [147].
Acute cellular rejection, occurring generally within 90
days of LT, concerns 50 to 75% of liver allograft recipients
[148]. The targets of activated lymphocytes are donor-
derived bile duct epithelial cells and vascular endothelium
[147].Acuterejectionisassociatedwithlymphocyticcholan-
gitis, a cytotoxic T-cell-mediated nonsuppurative destructive
cholangitis of the small intrahepatic bile ducts that can
inducecholestasis[147,149].ActivatedKuppfercellsmigrate
into the rejecting liver and release cytokines, resulting in
the loss of the Na(+), K(+)-ATPase activity, which plays an
important role in bile secretion [119]. Tauroursodeoxycholic
acid (TUDCA), a hydrophilic bile acid, can protect from
cholestatic and hepatocellular injury by enhancing the
secretory capacity of the cholestatic liver cells and by its
cytoprotective action against hydrophobic bile salts [150–
152]. During allograft rejection, the loss of Na(+), K(+)-
ATPase activity, a cotransporter for hepatocyte taurocholate
uptake, leads to impaired secretion of TUDCA and results
in subsequent cholestatic injury [119]. In patients presenting
ITBLs following LT, the response of lymphocyte T helper 1
(Th1)wasdecreased,whiletheresponseofTh2wasincreased
[153]. Whether these immunological changes were induced
by the damage of the bile ducts or occur as an additional
damaging factor or are found as an epiphenomen in patients
with liver transplant dysfunction remains unclear.
Although some studies did not show that chronic graft
rejection was a risk factor for development of ITBLs follow-
ing LT [154, 155], others demonstrated the association of
chronicallograftrejectionanddevelopmentofITBLs[33,46,
60, 66–68]. Chronic allograft rejection after LT also termed
“ductopenic rejection”, is characterized by ischemic injury
and paucity of bile ducts [148]. It occurs within the ﬁrst year
after LT with an incidence rate of 2 to 5% [156] .T h ez o n eo f
the central venous drainage or zone 3 of liver parenchyma
is poorest in oxygen concentration and more sensitiveJournal of Transplantation 7
to ischemia. During cellular chronic rejection, progressive
intimal and subintimal inﬁltration of second- and third-
order branches of the hepatic artery with foam macrophages
accompanied by foam cells or obliterative arteritis can result
in arterial stenoses and ultimately in ischemic injury to
interlobular bile ducts and hepatocytes of zone 3 [104, 157].
However,intheearlystagesofchronicrejection,thenecroin-
ﬂammatory lesions of interlobular bile ducts and hepato-
cytes, frequently associated with typical portal inﬂammatory
inﬁltrates of acute cellular rejection, seem more likely to be
the results of direct immune-mediated mechanisms [158].
8.3. Gender. Gender-mismatched liver transplant recipients
had a higher likelihood of graft failure when compared
withgender-matchedlivertransplantrecipients[74].Inmale
recipients receiving female donor organs there is an in-
creased risk of graft failure compared with a female recipient
receiving a liver from a male donor [74]. Moreover a female
to male donor/recipient match is associated with late occur-
rence of ITBLs [76].
8.4. Cytomegalovirus (CMV) Infection. The overall rate of
CMV infection in liver transplant recipients varies from
30 to 50% [159, 160]. In CMV-infected rat liver allografts
undergoing acute rejection there was a signiﬁcant increase
in portal inﬂammation and more severe bile duct injury
comparedwithCMV-negativeliverallografts[161].Intrans-
planted patients developping ITBLs during CMV infection,
histological examination of specimens from bile duct stric-
tures showed CMV inclusions [71]. CMV infection induces
injury of endothelial cells of the peribiliary capillary plexus,
with subsequent microthrombi formation and insuﬃcient
oxygenation of the biliary epithelium, ultimately leading to
ischemic injury of bile duct cells and development of ITBLs
[13, 72]. CMV infection can damage the bile duct cells in
a direct manner by infecting directly biliary epithelial cells
and in an indirect manner by immune attack evoked against
infected biliary epithelial cells [13].
8.5. Chemokine Polymorphism CCR5 Delta 32. Loss-of-
function mutation in the CC chemokine receptor 5
(CCR5delta32) has been associated with development of
ITBLs following LT [61]. Functional changes in the immune
system resulting from CCR-5 delta 32 mutation, which in-
clude impaired chemotaxis of regulatory T cells to the site
of injury may be responsible [162]. Indeed, a greater risk of
developing ITBLs after LT was observed in liver transplant
recipients carrying CCR5-delta 32 polymorphism compared
with CCR5 wild-type transplant recipients [13, 61, 73].
8.6. Metalloproteinase-2 (MMP-2) Polymorphism in Liver
Graft Donor and Recipient. A large family of proteolytic
enzymes involved in the degradation of extracellular matrix
called matrix metalloproteinases (MMPs), secreted by Kupf-
fer and stellate cells [163], are involved in the mechanisms of
neutrophil inﬁltration and in the alteration of liver microcir-
culationduetothelossofthenormalsinusoidalextracellular
matrix following cold [164]a n dw a r m[ 165, 166] I-R injury.
The activation of one of these MMPs, the metalloproteinase-
2 (MMP-2), also called Gelatinase-2, takes place at the cell
surface, which confers to this unique MMP a pivotal role
in cellular migration during processes requiring the remod-
elling of basement membranes, the thin extracellular matri-
ces underlying endothelial and epithelial cells [167, 168].
MMPs are subject to complex regulation at multiple lev-
els: gene transcription, proenzyme activation, and inhibition
of activity by tissue inhibitors of matrix metalloproteinases
(TIMPs) [167, 168]. At gene level, it has been demonstrated
that several single nucleotide polymorphisms (SP) in the
genepromoterregionsofMMPshaveanimpactonthetrans-
cription rate into the cells [169, 170]. The SP C/T transition
at position—1306 in the promoter of MMP-2, abolishes the
single polymorphism 1 binding site and leads to decreased
mRNA transcription and protein expression of MMP-2 [169,
170]. After LT, in association with the–1306 CT genotype
of donor and recipient, the serum levels of MMP-2 were
decreased in patients that developed ITBLs [75].
MMP-2 CT genotype in both, donor and recipient is
strongly and independently related to the development of
ITBLs within 4 years after LT [75]. The presence of the
MMP-2 CT genotype in donor and/or recipient was found
to increase the incidence of ITBLs incidence stepwise from
9% when absent, increasing to 16% when present in either
donor or recipient, further increasing to 29% when present
inbothdonorandrecipient[75].Theseﬁndingsindicatethat
a genetically determined reduced MMP-2 tissue remodelling
contributes to the development of ITBLs after LT.
9. ExtendedDonor CriteriaandITBLs
9.1. Donor Age and ITBLs. As old livers are more susceptible
to warm and cold I-R injury than young livers [117–172],
donor age seems to be a relevant risk factor in the develop-
ment of ITBLs after LT [4, 12, 36, 37, 76, 173].
The activation of peroxisome proliferators-activated re-
ceptor gamma (PPARγ), which belongs to the hormone nu-
c l e a rr e c e p t o rs u p e r f a m i l y[ 174], is signiﬁcantly reduced in
old mice compared to young mice [175]. During liver ische-
mia, its activation is suppressed [176]. In old mice, PPARγ
activation signiﬁcantly improves liver I-R injury [176]b y
modulating inﬂammatory response and apoptosis [177].
Diﬀerent from young livers, the initiation of apoptosis
by nonparenchymal cells in older livers is increased and is
driven by the enhanced release of TNFα [171]. TNFα is a
cytokine mainly released by activated Kupﬀer cells following
liver I-R [19, 178, 179]. Aging may directly aﬀect Kupﬀer
cells resulting in TNFα release [180, 181] and apoptosis
[171]. Apoptosis is a highly regulated ATP-requiring form
of cell death [182]. Despite decreased ATP levels and reduc-
ed hepatic mitochondrial function in older livers [117], apo-
ptosis seems to be a predominant feature of liver cell death
following ischemic injury in these old livers [171]. Lower
ATP content in older liver does not directly aﬀect the apo-
ptotic cascade but facilitates the activation of apoptotic med-
iators and inhibits survival mechanisms [171].8 Journal of Transplantation
9.2. Cold Ischemia Time and ITBLs. Prolonged cold ischemia
time is an independent risk factor for liver preservation
injury, even more so than donor age [183]. Cold graft preser-
vationformorethan14hhasbeenassociatedwithatwo-fold
increase in preservation injury, resulting in biliary stricures
and decreased graft survival [183–185]. Accordingly, the
risk of graft loss increases by 1% for each additional hour
of cold ischemia [186]. Although several studies failed to
show a correlation between the incidence of ITBLs and cold
ischemia time [44, 68, 155, 173, 187, 188], in other studies
this incidence was increased after a prolonged cold ischemia
time [2, 12]. After a cold ischemia time less than 13 hours
the percentage of ITBLs was 7%, whereas the percentage
increased to 52% when the cold ischemia time was longer
than 13 hours, and to 69% if it was longer than 15 hours
[2, 12]. In a recent large retrospective study with an overall
incidence of post liver transplantation ITBLs of 3.9% [12],
10hoursofcoldischemiatimeturnedouttobethethreshold
that should not be excessed in order to avoid ITBLs, [12].
9.3. NHBDs and ITBLs. In liver transplantation, the use of
NHBDs has been introduced in order to expand the organ
donor pool [189]. However, the addition of donor warm
ischemia time to the subsequent cold preservation time and
warm reperfusion injury negatively impacts graft function
following LT [190].
Compared with donation after brain death (DBD), livers
from NHBD inevitably sustain a period of warm ischemia
from circulatory arrest until start of preservation, resulting
in ischemic injury with higher risk of biliary complications
including ITBLs [39]. Also the incidence of IPGF, PNF, acute
and chronic rejection, and retransplantation is higher with
NHBD [190–194].
In liver transplantation, the overall rate of biliary com-
plications is 29% (range: 11%–53%) for NHBD and 17%
(9%–22%) for DBD recipients [190] .T h eI T B Lr a t ei s1 6 %
(8%–38%) for NHBD recipients and 3% (0%–8%) for DBD
recipients [39, 52, 190, 192–195]. ITBLsoccurwithin 30 days
in NHBD and about 3 months after transplantation in DBD
grafts [4].
In NHBD, low blood ﬂow during the period of hypoten-
sion after tracheal extubation and no blood ﬂow during
the period between cardiac arrest and organ recovery result
in formation of microthrombi that obstruct the capillaries
and limit liver perfusion [196]. Inadequate ﬂush of these
capillaries leads to suboptimal cold preservation and subse-
quently to exacerbated ischemic injury [196]. In a pig NHBD
model of liver transplantation, prolonged warm ischemia
time resulted in a high biliary salt-to-phospholipid ratio,
which contributes to the development of ITBLs [51].
9.4. Graft Steatosis and ITBLs. Steatosis of the liver is con-
sidered pathologic when the hepatic fat content, consisting
mainlyoftriglycerides,exceeds5%oftheactualwetweightof
the liver [197]. Hepatic steatosis is present in approximately
20% of liver donors, and 5-6% of cadaveric livers are
discarded due to steatosis [198]. Liver steatosis is histo-
logically classed as “macrovesicular” when the hepatocytes
are distended by a single large fat vacuole that displaces
the nucleus to one side of the cell and as “microvesicular”
when multiple small droplets ﬁnely are dispersed in the
cytoplasm without nuclear displacement [197]. More than
30% of macrovesicular steatosis on donor liver biopsy is an
independent risk factor for allograft loss at one year along
with other elements of the donor risk index [199]. Early
biliary complications seems to be associated with moderate
macrovesicular steatosis [200, 201]. In a recent study, the
time interval between portal and arterial reperfusion and
macrovesicular steatosis of the graft of more than 25%
revealed to be signiﬁcant predictors of biliary complications
[40, 41]. At Univariate analysis macrosteatosis of more of
25% of the graft is the only independent risk factor pre-
dicting biliary complications after liver transplantation [40,
41]. The increased susceptibility of the steatotic liver to I-
R injury is due to the perturbation of both, blood ﬂow
microcirculation and changes in the cells [202]. Brain death
of the liver donor may amplify the adverse eﬀects of pre-
existing steatosis by inducing hypotension, and reducing
portal venous and hepatic microcirculation [203, 204].
10. Storage Solutions and Perfusion Methods of
the LiverGraft and ITBLs
10.1. Graft Perfusion and ITBLs. Although approximately
75% of the total liver blood ﬂow is provided by the portal
vein, the hepatic artery supplies approximately 50% of the
oxygen consumed by the liver in physiologic conditions
[205]. There are two main methods for revascularization of
the liver graft: sequential and simultaneous revascularization
[42]. In the ﬁrst method, sequential revascularization, the
graft is ﬁrst reperfused via either the portal vein or the hep-
atic artery (anterograde reperfusion), or via the inferior vena
cava (IVC) (retrograde reperfusion) with subsequent recon-
struction of the remaining vessels. In the second method,
simultaneousrevascularization,thegraftisreperfusedsimul-
taneously via the portal vein and the hepatic artery. The
sequence of graft reperfusion may be relevant for the
development of ITBLs, particularly in grafts from ECD [42].
Liver transplantation standard technique involves initial
blood perfusion by the portal vein to shorten the anhepatic
period and graft rewarming in situ. In this period, the
graft is exclusively perfused through the portal vein for at
least 10min until the realization of the hepatic arterial ana-
stomosis [40]. The delay of rearterialization in sequential
revascularizationisassociatedwithmorepronouncedmicro-
vascular disturbances and subsequent graft dysfunction
[206]. Indeed rearterialization of the graft during liver
transplantation causes an increased volumetric blood ﬂow
within the sinusoids called “reactive hyperemia” [207]. A
long interval between portal and arterial reperfusion of the
liver, in case of sequential revascularization, is associated to
a higher incidence of biliary complications following DBD
LT [40]. Simultaneous revascularization elicits a remarkable
improvement in oxygen tension and maintenance of tissue
ATP, compared to sequential revascularization [208]. The
disadvantage of simultaneous revascularization is the pro-
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whichcan be detrimental to postoperative graftfunction and
survival [184, 209].
Whether simultaneous revascularization is better than
sequential revascularization remains unclear [42, 207, 210,
211].
In some retrospective studies, the incidence of ITBLs
in patients who underwent simultaneous revascularization
of the graft [45, 212] was lower compared to patients who
had sequential revascularization [42, 211]. Particularly in a
recent study, simultaneous revascularization resulted in a
minor incidence of ITBls compared to sequential revascu-
larization (none versus 26%, resp.) [213], suggesting that
simultanous revascularization may be more suitable to pro-
tect the integrity of the intrahepatic biliary tree [213].
Retrograde perfusion of the liver graft via the vena cava,
followed by anterograde sequential reperfusion of the portal
vein and the hepatic artery, decreases liver I-R injury and
IPGF [210]. However, on the biliary epithelium or other cells
of the biliary tract retrograde reperfusion has detrimental
eﬀectswithanincreasedriskofITBLs[210].Improvementin
ﬂushingthemicroscopicbiliaryvasculatureandpossiblypre-
venting microvascular thrombosis in the biliary tree may be
obtained by adding the high-pressure aortal perfusion tech-
nique to the main graft perfusion methods, [66] and addi-
tional arterial back-table pressure perfusion [36]. These graft
perfusion methods seem to reduce the rate of ITBLs follow-
ing LT [36, 66].
10.2. ITBLs: Importance of Portal Venous Blood Flow. The
blood supply to the biliary tree is almost solely arterial, with
no signiﬁcant contribution from the portal vein in physi-
ological conditions [31, 214, 215]. However, some support
the hypothesis that the peribiliary vascular plexus is not only
sustained by blood from the hepatic artery as traditionally
reported, but also by blood from the portal vein [216]. The
hepatic artery is in essence an end artery for the donor
biliary tree, as collaterals from the lower extrahepatic biliary
tree are interrupted in the process of liver procurement
and transplantation. In case of hepatic artery thrombosis,
new collateral vessels can form and limit additional biliary
stricture formation [155]. As ITBLs occur in the absence of
hepatic arterythrombosis, it has been suggestedthat the por-
tal venous blood ﬂow has an important impact on the patho-
genesis of ITBLs after liver transplantation [216]. In a recent
study, patients with partial portal vein thrombosis and intact
hepatic arterial blood supply developed ITBLs in the hepatic
segments aﬀected by portal vein thrombosis [216]. In many
cases of hepatic artery thrombosis it seems that the portal
perfusion maintains hepatocytes [216]. Thus, the contribu-
tion of the portal blood ﬂow to the biliary microcirculation
is not negligible and a compromised portal venous blood
supply can predispose to the development of ITBLs [216].
10.3. Static Cold Storage Solutions of the Graft and ITBLs.
Liver preservation techniques do inﬂuence the graft quality
[9]. Static and dynamic preservation are the two current
methods of liver preservation in LT [217]. Static preservation
means simple cold storage while dynamic preservation com-
prises hypothermic machine perfusion, normothermic
machine perfusion, and oxygen persuﬄation [217]. Until
today, only static cold storage preservation is clinically ap-
proved for liver transplantation in humans [217].
Coldpreservationinjuriestothebiliarytractofthedonor
liver were decreased by eﬃcient ﬂushing of the biliary tract
in animals [218, 219] and in humans [220, 221]. In a recent
study, an eﬀective biliary ﬂush reduced the eﬀects of bile
salt toxicity to the epithelium, reduced cell edema, prevented
cell acidiﬁcation, and provided adequate ATP precursor
substances,resultinginreductionofbiliarycoldpreservation
injuries [222]. Generally, static cold storage UW solution is
used for organ preservation [223], however the histidine-
tryptophan-ketoglutarate (HTK)staticpreservationsolution
has started to compete with UW [224] and is now mainly
used in deceased donor liver transplantation (DDLT) in
Europe and North America and in living-related liver
transplantation (LRLT) in Japan and Hongkong [43, 221,
225–233]. UW cold storage solution has more hepatocyto-
protective eﬀects than HTK cold storage solution [234–236],
but its viscous nature may hinder an eﬃcient ﬂushing of the
small bile duct capillaries, so residual bile can crystallize and
obstruct capillary ducts, thus aggravating the cold ischemic
insult to the epithelial biliary cells [237, 238]. HTK cold stor-
age solution has the same viscosity as water and its average
velocity is three times greater than UW solution under the
same perfusionpressure [221]. The time of liver cooling with
HTKcoldstoragesolutionisshorterandimprovestheperfu-
sion of the biliary vascular plexus resulting in reduced biliary
tract preservation injury [36, 220, 221, 239, 240]. Also the
lack of macroaggregate formation of adenosine crystals and
the absence of plastic byproducts in HTK solution, responsi-
ble for occlusion of small capillaries, which exacerbates small
bile duct ischemia following reperfusion, contribute to the
beneﬁcial eﬀects of HTK cold storage solution [237, 238].
HTK cold storage solution may be used particularly in livers
with existing I-R injury, with high risk of I-R injury, or
with biliary injury such as ECD organs [221, 223, 241]. A
combined use of both cold storage solutions, HTK with its
low viscosity and UW with its hepatocytoprotective eﬀects,
mayhaveadditionalbeneﬁtsforthebiliarysystem[219,242].
Thrombolytic agents as urokinase [243], which may help
ﬂushing the microscopic biliary vasculature, were employed
topreventmicrovascularthrombosisinthebiliarytree[244].
As there are no standardized guidelines regarding the
methods of liver graft perfusion in terms of solution type,
amount of solution, route of perfusion, perfusion pressure,
and the time of perfusion, adequately powered randomized
clinical trials with long follow-up periods are needed to
evaluate the long-term impact on warm and cold I-R injury
and induction of ITBLs after LT.
11. Conclusion
The main pathomechanisms leading to ITBLs following LT
are cold and warm I-R injury, stagnation of cytotoxic bile
salts and changes in bile composition, and immunological
mechanisms. These mechanisms are mutually connected,
one inducing or reinforcing the other, that it may be diﬃcult
sometimes to settle the “culprit”. Besides, knowledge of these10 Journal of Transplantation
mechanisms remains superﬁcial and in the beginnings. Nat-
urally, that goes too for the possibilities of ITBL prevention
and treatment. Until sustained progressions are not made in
the ﬁeld of ITBL research, the only way to keep the incidence
of ITBLs after LT as low as possible is to reduce as much as
possible their risk factors.
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